3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
243
Melanoma
142
Squamous Cell Carcinoma of Head and Neck
139
Parkinson Disease 4, Autosomal Dominant Lewy Body
119
Neoplasm Metastasis
105
Triple Negative Breast Neoplasms
97
Lung Neoplasms
91
Neoplasms
90
Breast Neoplasms
80
Colorectal Neoplasms
70
Carcinoma, Renal Cell
70
Head and Neck Neoplasms
59
Urinary Bladder Neoplasms
50
Stomach Neoplasms
47
Ovarian Neoplasms
47
Endometrial Neoplasms
46
Carcinoma, Transitional Cell
44
Carcinoma, Hepatocellular
35
Uterine Cervical Neoplasms
34
Pancreatic Neoplasms
34
Esophageal Neoplasms
27
Recurrence
26
Prostatic Neoplasms
26
Carcinoma, Squamous Cell
25
Carcinoma
25
Sarcoma
24
Glioblastoma
23
Brain Neoplasms
23
Hodgkin Disease
19
Cholangiocarcinoma
19
Interventions
Bevacizumab
3
contrast agent BR1
2
pralsetinib
1
pembrolizumab
1
Pemetrexed
1
Paclitaxel
1
Microbubbles
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Biopsy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Nerve Tissue
×
pembrolizumab
×
1 year
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts